- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%? | 1 | The Motley Fool Australia | ||
| Mi | Wednesday's HotCopper trends: Adisyn, SciDev, Neuren Pharmaceuticals and other daily topics | 3 | The Market Online Australia | ||
| Mi | Lunch Wrap: ASX pops above record line as Neuren catches fire | 5 | Stockhead | ||
| Mi | Neuren Pharmaceuticals Reports Record Q2 DAYBUE Sales, Upgrades Full-Year Royalty Forecast | 4 | Finance News Network | ||
| Mi | Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade | 2 | The Motley Fool Australia | ||
| Mi | NEUREN PHARMACEUTICALS LIMITED: Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded | 1 | ASX | ||
| 24.07. | NEUREN PHARMACEUTICALS LIMITED: Neuren highlights participation in PMSF Family Conference | - | ASX | ||
| 29.06. | The ASX Today: Tech leads bourse as Neuren surges on major European approval boost | 7 | The Market Online Australia | ||
| NEUREN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 29.06. | Monday's HotCopper trends: Comms Group, Neuren Pharma, SRJ Tech, and other daily topics | 7 | The Market Online Australia | ||
| 29.06. | Health Check: No more monkey business as European regulators approve flagship Neuren drug | 2 | Stockhead | ||
| 29.06. | Neuren Pharmaceuticals welcomes milestone approval for Daybu | 4 | The Market Online Australia | ||
| 29.06. | Neuren Pharmaceuticals (ASX:NEU) US$35m EU trigger puts royalties back in focus | 2 | Stocks Down Under | ||
| 29.06. | Neuren's DAYBU Receives Positive EU Recommendation for Rett Syndrome Treatment | 1 | Finance News Network | ||
| 28.06. | NEUREN PHARMACEUTICALS LIMITED: DAYBU recommended for approval in the European Union | - | ASX | ||
| 18.06. | NEUREN PHARMACEUTICALS LIMITED: Application for quotation of securities - NEU | 5 | ASX | ||
| 01.06. | NEUREN PHARMACEUTICALS LIMITED: Notification of cessation of securities - NEU | - | ASX | ||
| 01.06. | NEUREN PHARMACEUTICALS LIMITED: Notification regarding unquoted securities - NEU | - | ASX | ||
| 27.05. | NEUREN PHARMACEUTICALS LIMITED: Results of Meeting | 4 | ASX | ||
| 27.05. | NEUREN PHARMACEUTICALS LIMITED: AGM Chair Address & CEO Presentation | 4 | ASX | ||
| 18.05. | Dr Boreham's Crucible: Neuren looks beyond Rett as Daybue royalties surge | 7 | Stockhead |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANTHERA PHARMACEUTICALS | 16,920 | -0,12 % | Santhera Pharmaceuticals Holding AG: Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus | Pratteln, Switzerland, July 13, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,682 | -0,01 % | Citius Pharmaceuticals, Inc. - 8-K, Current Report | ||
| MILESTONE PHARMACEUTICALS | 1,220 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 | ||
| BAYER | 49,810 | +0,83 % | DAX vor spannender Woche - und Rekorden? Bayer, Siemens Energy, Commerzbank und Allianz mit ... | Ungeachtet der geopolitischen Krisenherde könnte die überwiegend positiv aufgenommene Berichtssaison der DAX-Konzern auch in der neuen Woche Rückenwind verleihen. Sinkende Ölpreise und starke Quartalszahlen... ► Artikel lesen | |
| MERCK KGAA | 143,65 | -1,03 % | Ihre wichtigsten Termine: Alle Analysten-Augen auf: Rheinmetall, Deutsche Telekom, Siemens, Airbnb & Lyft | © Foto: Julian Stratenschulte/dpa Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 79,33 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY | 1,890 | 0,00 % | Zhengye Biotechnology regains Nasdaq bid price compliance; shares down | ||
| ETON PHARMACEUTICALS | 44,560 | -0,09 % | Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 | ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL (propranolol hydrochloride)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,880 | -0,04 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| OMNIAB | 3,080 | 0,00 % | OmniAb GAAP EPS of -$0.05 beats by $0.07, revenue of $13.4M beats by $8.71M | ||
| LB PHARMACEUTICALS | 47,960 | -0,08 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Announces $150 Million Private Placement | NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact... ► Artikel lesen | |
| SCHOTT PHARMA | 22,500 | +2,74 % | UBS stuft Schott Pharma auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Schott Pharma von 25,90 auf 26,50 Euro angehoben und die Einstufung auf "Buy" belassen. Das neue Kursziel reflektiere den... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,945 | +0,13 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 14,340 | 0,00 % | Generate Biomedicines, Inc. - 10-Q, Quarterly Report | ||
| GSK | 22,860 | +1,06 % | BERNSTEIN RESEARCH stuft GSK auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für GSK von 2825 auf 3010 Pence angehoben und die Einstufung auf "Outperform" belassen. Die Nachhaltigkeit des Geschäfts... ► Artikel lesen |
Das Unternehmen NEUREN PHARMACEUTICALS LIMITED kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,84 % bei einem Aktienkurs von 14,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUREN PHARMACEUTICALS LIMITED finden Sie auf Wallstreet Online.